These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists. Noble GR; Bernier RH; Esber EC; Hardegree MC; Hinman AR; Klein D; Saah AJ JAMA; 1987 Mar; 257(10):1351-6. PubMed ID: 3820444 [TBL] [Abstract][Full Text] [Related]
44. Using the Australian Childhood Immunisation Register to track the transition from whole-cell to acellular pertussis vaccines. Torvaldsen S; Hull BP; McIntyre PB Commun Dis Intell Q Rep; 2002; 26(4):581-3. PubMed ID: 12549528 [TBL] [Abstract][Full Text] [Related]
45. Benefits and risks of immunization against pertussis. Stuart-Harris C Dev Biol Stand; 1979; 43():75-83. PubMed ID: 520687 [TBL] [Abstract][Full Text] [Related]
46. Metabolic and hematologic effects and immune complex formation related to pertussis immunization. Mink CM; Uhari M; Blumberg DA; Knip M; Lewis K; Christenson PD; Toyoda M; Jordan SC; Levin SR; Cherry JD Pediatr Res; 1990 Apr; 27(4 Pt 1):353-7. PubMed ID: 2188202 [TBL] [Abstract][Full Text] [Related]
48. Introduction to the International Symposium on Pertussis Evaluation and Research on Acellular Pertussis Vaccines. Oya A Dev Biol Stand; 1991; 73():3-4. PubMed ID: 1778323 [No Abstract] [Full Text] [Related]
49. Safety follow-up in a cohort of Biken acellular DPT vaccine recipients in Japan. Chazono M; Hirota T; Yoshida I; Konobe T; Takaku K; Fukai K Dev Biol Stand; 1991; 73():323-7. PubMed ID: 1778326 [TBL] [Abstract][Full Text] [Related]
50. Effectiveness of acellular pertussis vaccine in a routine immunization program: a multicenter, case-control study in Japan. Ohfuji S; Okada K; Nakano T; Ito H; Hara M; Kuroki H; Hirota Y Vaccine; 2015 Feb; 33(8):1027-32. PubMed ID: 25596459 [TBL] [Abstract][Full Text] [Related]
51. Whooping cough and pertussis vaccine: a comparison of risks and benefits in Britain during the period 1968-83. Stewart GT Dev Biol Stand; 1985; 61():395-405. PubMed ID: 3835080 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. Onorato IM; Wassilak SG; Meade B JAMA; 1992 May; 267(20):2745-9. PubMed ID: 1578592 [TBL] [Abstract][Full Text] [Related]
54. Protection against pertussis by acellular pertussis vaccines (Takeda, Japan): household contact studies in Kawasaki City, Japan. Kato T; Goshima T; Nakajima N; Kaku H; Arimoto Y; Hayashi F Acta Paediatr Jpn; 1989 Dec; 31(6):698-701. PubMed ID: 2516396 [TBL] [Abstract][Full Text] [Related]
55. Update on pertussis and diphtheria-tetanus toxoids-pertussis vaccination new strategies for clinicians. Introduction. Cherry JD Pediatr Infect Dis J; 1997 Apr; 16(4 Suppl):S76-7. PubMed ID: 9109160 [No Abstract] [Full Text] [Related]
56. [Epidemiology of pertussis and studies on culture positive pertussis cases in Japan]. Kimura M; Kuno-Sakai H; Kunita N; Isomura S; Funahashi M; Sato Y Kansenshogaku Zasshi; 1996 Jan; 70(1):19-28. PubMed ID: 8822050 [TBL] [Abstract][Full Text] [Related]
57. Revisiting the possibility of serious adverse events from the whole cell pertussis vaccine: were metabolically vulnerable children at risk? Wilson K; Potter B; Manuel D; Keelan J; Chakraborty P Med Hypotheses; 2010 Jan; 74(1):150-4. PubMed ID: 19660877 [TBL] [Abstract][Full Text] [Related]
58. Current epidemiology of pertussis in Japan. Kimura M; Kuno-Sakai H Pediatr Infect Dis J; 1990 Oct; 9(10):705-9. PubMed ID: 2235143 [TBL] [Abstract][Full Text] [Related]
59. [Protection against pertussis by Japanese T type acellular pertussis vaccine: household contact study in Kawasaki City]. Kato T; Matsuyoshi S; Goshima T; Nakajima N; Yamamoto H; Arimoto Y; Kaku H; Hayashi F Kansenshogaku Zasshi; 1989 Sep; 63(9):986-90. PubMed ID: 2509597 [TBL] [Abstract][Full Text] [Related]